FLT3 and acute myeloid leukemia: We demonstrated the ability of midostaurin to behave as a chemosensitizer of numerous chemotherapeutic and targeted agents, such inhibitors of proviability signalling molecules, against AML cells regardless of their FLT3 mutational status.